Darren Feldman, MD
Dr. Feldman is an Assistant Attending Physician on the Genitourinary Oncology Service and Bone Marrow Transplant (BMT) Service within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC) and Assistant Professor in Medicine at Weill Medical College of Cornell University, both in New York City, NY. He completed his Internal Medicine residency at New York University before serving as chief resident for the Department of Medicine at MSKCC, where he went on to complete fellowship in medical oncology and hematology. Dr. Feldman’s research focuses on understanding the biology and improving the treatment for patients with germ cell tumors (GCT) and kidney tumors. He is also interested in the mechanism and management of late toxicities resulting from GCT treatment, particularly effects on the cardiovascular system. At MSKCC, he oversees the GCT medical oncology research program and is director of the BMT Solid Tumor program. He has led and is currently leading national and international trials in the treatment of GCT and kidney cancer and has presented his research at meetings around the world. Dr. Feldman is the recipient of several awards including the John Mendelsohn Teaching Award and the Paul Sherlock Housestaff Teaching Award for the Department of Medicine at MSKCC and has been recognized in New York Magazine’s Top Doctors in New York City. He has also received several research grants including an ASCO Conquer Cancer Foundation Young Investigator Award, an Aflac / Children’s Oncology Group Adolescent and Young Adult Biology Research Grant, a Movember GAP5 award, and a Cycle for Survival award. Dr. Feldman has published more than 100 peer-reviewed publications on urologic malignancies and authored review chapters in several prominent text books including Harrison’s Principles of Internal Medicine, DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, and the Comprehensive Textbook of Genitourinary Oncology.
Financial relationships
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:TelixDate added:Date updated:11/04/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Specialty Not Specified)Ineligible company:DecibelDate added:Date updated:11/04/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Specialty Not Specified)Ineligible company:AstellasDate added:Date updated:11/04/2022